Insider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Purchases 38,880 Shares of Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. bought 38,880 shares of Oncocyte stock in a transaction that occurred on Friday, April 24th. The stock was bought at an average price of $3.53 per share, with a total value of $137,246.40. Following the purchase, the insider owned 12,433,961 shares of the company’s stock, valued at $43,891,882.33. This trade represents a 0.31% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 27th, Broadwood Partners, L.P. purchased 250,923 shares of Oncocyte stock. The shares were purchased at an average price of $3.64 per share, for a total transaction of $913,359.72.
• On Thursday, April 23rd, Broadwood Partners, L.P. purchased 280,381 shares of Oncocyte stock. The stock was purchased at an average cost of $3.50 per share, with a total value of $981,333.50.
• On Monday, April 20th, Broadwood Partners, L.P. purchased 40,690 shares of Oncocyte stock. The stock was purchased at an average cost of $3.88 per share, with a total value of $157,877.20.
• On Friday, April 17th, Broadwood Partners, L.P. acquired 40,114 shares of Oncocyte stock. The stock was purchased at an average price of $3.57 per share, with a total value of $143,206.98.
• On Thursday, April 16th, Broadwood Partners, L.P. acquired 102,057 shares of Oncocyte stock. The shares were purchased at an average cost of $3.45 per share, for a total transaction of $352,096.65.
• On Tuesday, February 10th, Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock. The shares were purchased at an average price of $5.75 per share, for a total transaction of $2,999,999.25.

Oncocyte Trading Up 2.1%

Shares of NASDAQ IMDX traded up $0.08 during trading hours on Monday, reaching $3.84. The stock had a trading volume of 454,644 shares, compared to its average volume of 175,570. The company has a market capitalization of $123.53 million, a P/E ratio of -2.37 and a beta of 1.52. Oncocyte Corp has a twelve month low of $2.33 and a twelve month high of $8.51. The stock has a fifty day moving average price of $4.38.

Oncocyte (NASDAQ:IMDX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $1.14 million for the quarter.

Analyst Ratings Changes

A number of analysts recently weighed in on IMDX shares. Lake Street Capital upped their target price on shares of Oncocyte from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Wall Street Zen cut shares of Oncocyte from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncocyte in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.